Treatment for dopaminergic disorders
US9463186B2 · kind B2 · utility
1Cited by
46References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 15, 2014 |
| Grant date | Oct 11, 2016 |
| Priority date | — |
| Expiry date | Apr 19, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/135
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides systems, compositions and methods for treatment of dopaminergic disorders (e.g., Parkinson's disease) using the combination of a first compound that inhibits a voltage-gated calcium channel of the type Cav1.3 (e.g., a dihydropyridine such as isradipine), and a second compound that is monoamine oxidase inhibitor and/or is a nitric oxide synthase inhibitor (e.g., rasagiline or derivative thereof).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.